Related Experiment Video
Updated: Jun 3, 2026
Minimally Invasive Endoscopic Intracerebral Hemorrhage Evacuation
Published on: October 15, 2021
Statin use and outcome after intracerebral hemorrhage: case-control study and meta-analysis
A Biffi1, W J Devan, C D Anderson
1Center for Human Genetic Research, Massachusetts General Hospital, 185 Cambridge Street, CPZN-6818, Boston, MA 02114, USA.
Insights
Pre-intracerebral hemorrhage (ICH) statin use is linked to better outcomes and lower mortality in elderly patients. This meta-analysis confirms statins improve recovery and survival after ICH, suggesting a class effect.
Area of Science:
- Neurology
- Cardiovascular Medicine
- Geriatrics
Background:
- Intracerebral hemorrhage (ICH) is a leading cause of death in the elderly.
- Statin use is prevalent in this demographic.
- Previous studies on statins' effect on ICH outcomes are inconsistent.
Purpose of the Study:
- To determine if pre-ICH statin exposure improves functional outcomes and reduces mortality.
- To conduct a meta-analysis of existing and unpublished data on statin use and ICH.
Main Methods:
- A cohort study compared 90-day outcomes in 238 pre-ICH statin users and 461 non-users.
- A random-effects model meta-analysis combined this cohort with published studies.
- Total analysis included 698 statin users and 1,823 non-users.
Main Results:
- Statin use before ICH was associated with a higher probability of favorable 90-day functional outcome (OR=2.08).
- Pre-ICH statin use significantly reduced 90-day mortality (OR=0.47).
- Meta-analysis confirmed these findings, showing improved outcomes (OR=1.91) and reduced mortality (OR=0.55) post-ICH.
Conclusions:
- Antecedent statin use is associated with improved outcomes and survival after ICH.
- The observed benefit appears to be a class effect of statins.
- Further research is needed to elucidate the underlying biological mechanisms.
Objectives:
Intracerebral hemorrhage (ICH) is a highly lethal disease of the elderly. Use of statins is increasingly widespread among the elderly, and therefore common in patients who develop ICH. Accumulating data suggests that statins have neuroprotective effects, but their association with ICH outcome has been inconsistent. We therefore performed a meta-analysis of all available evidence, including unpublished data from our own institution, to determine whether statin exposure is protective for patients who develop ICH.
Methods:
In our prospectively ascertained cohort, we compared 90-day functional outcome in 238 pre-ICH statin cases and 461 statin-free ICH cases. We then meta-analyzed results from our cohort along with previously published studies using a random effects model, for a total of 698 ICH statin cases and 1,823 non-statin-exposed subjects.
Results:
Data from our center demonstrated an association between statin use before ICH and increased probability of favorable outcome (odds ratio [OR] = 2.08, 95% confidence interval [CI] 1.37-3.17) and reduced mortality (OR = 0.47, 95% CI 0.32-0.70) at 90 days. No compound-specific statin effect was identified. Meta-analysis of all published evidence confirmed the effect of statin use on good outcome (OR = 1.91, 95% CI 1.38-2.65) and mortality (OR = 0.55, 95% CI 0.42-0.72) after ICH.
Conclusion:
Antecedent use of statins prior to ICH is associated with favorable outcome and reduced mortality after ICH. This phenomenon appears to be a class effect of statins. Further studies are required to clarify the biological mechanisms underlying these observations.
Related Concept Videos
01:17Hemorrhagic Stroke l: Introduction
01:29Hemorrhagic Stroke ll: Pathophysiology